Dashboard
Manage Tickers

PALI PALISADE BIO, INC.

Nasdaq palisadebio.com


$ 1.86 $ 0.12 (6.9 %)    

Monday, 20-Oct-2025 17:29:39 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 1.86
$ 1.73
$ 1.80 x 255
$ 1.87 x 96
$ 1.66 - $ 1.89
$ 0.53 - $ 4.32
3,778,920
na
16.96M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-24-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-26-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-23-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-22-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 03-27-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 03-22-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 04-02-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-23-2017 12-31-2016 10-K
36 11-08-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 03-14-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

palisade-bio-doses-the-first-patients-in-its-phase-1b-study-of-pali-2108-a-first-in-class-ileocolonic-targeted-pde4-inhibitor-prodrug-for-fibrostenotic-crohns-diseasea-condition-with-no-approved-therapies
Palisade Bio Doses The First Patients In I...
10/20/2025 12:48:57

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies...

palisade-bio-secures-canadian-patent-for-pali-2108-gut-activated-pde4-bd-inhibitor-targeting-fscd-and-uc
Palisade Bio Secures Canadian Patent For P...
10/13/2025 12:49:01

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's diseas...

steven-cohen-doubles-the-sp-500--and-his-next-bets-all-gut
Steven Cohen Doubles The S&P 500 — And His...
10/08/2025 15:30:40

Steven Cohen's Point72 Asset Management has doubled the S&P 500's three-year return and is investing in this biotec...

why-amd-shares-are-trading-higher-by-over-34-here-are-20-stocks-moving-premarket
Why AMD Shares Are Trading Higher By Over ...
10/06/2025 13:01:08

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
10/06/2025 12:08:40

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
10/03/2025 12:08:34

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/02/2025 17:06:31

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/02/2025 12:09:25

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/01/2025 17:06:01

palisade-bio-prices-120m-public-offering-of-171440559-shares-at-070share
Palisade Bio Prices $120M Public Offering ...
10/01/2025 13:21:04

Palisade Bio, Inc.  (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company foc...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/01/2025 12:09:24

palisade-bio-adjourns-special-stockholder-meeting-due-to-lack-of-quorum
Palisade Bio Adjourns Special Stockholder ...
09/18/2025 20:08:56

palisade-bio-releases-pali-2108-phase-1b-clinical-data-demonstrating-100-clinical-response-regarding-efficacy-of-pali-2108-in-ulcerative-colitis
Palisade Bio Releases PALI-2108 Phase 1b C...
09/17/2025 13:05:46

PALI-2108 demonstrated favorable safety, with no serious adverse events, lab abnormalities, or EKG concernsPhase 1b data demons...

palisade-bio-receives-health-canada-clearance-to-initiate-phase-1b-study-of-pali-2108-in-fibrostenotic-crohns-disease
Palisade Bio Receives Health Canada Cleara...
09/05/2025 12:47:20

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies...

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
08/11/2025 21:06:28

palisade-bio-reports-phase-1-results-for-pali-2108-showing-safety-and-strong-colon-tissue-drug-levels-as-company-prepares-for-phase-2-trial-in-2026
Palisade Bio Reports Phase 1 Results For P...
08/07/2025 13:16:47

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs)Extended half-life and local bioactiv...

palisade-bio-secures-china-patent-for-pali-2108-a-targeted-pde4-inhibitor-for-crohns-disease-and-ulcerative-colitis
Palisade Bio Secures China Patent For PALI...
07/31/2025 12:46:19

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's diseas...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/24/2025 12:08:09

why-alphabet-shares-are-trading-higher-here-are-20-stocks-moving-premarket
Why Alphabet Shares Are Trading Higher; He...
07/24/2025 09:23:22

palisade-bio-raises-39m-through-exercise-of-43m-warrants-at-09047share-issues-86m-new-warrants-at-same-price
Palisade Bio Raises $3.9M Through Exercise...
07/24/2025 00:44:32

Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company focu...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION